Howard Fillit
Overview
Explore the profile of Howard Fillit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
71
Citations
2549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang L, Hu W, Dong F, Sheng C, Wu J, Han Y, et al.
Geroscience
. 2025 Jan;
PMID: 39888585
Brain network dynamics have been extensively explored in patients with subjective cognitive decline (SCD). However, these studies are susceptible to individual differences, scanning parameters, and other confounding factors. Therefore, how...
2.
Cummings J, Gold M, Mintun M, Irizarry M, von Eschenbach A, Hendrix S, et al.
J Prev Alzheimers Dis
. 2025 Jan;
12(1):100001.
PMID: 39800453
There is growing consensus in the Alzheimer's community that combination therapy will be needed to maximize therapeutic benefits through the course of the disease. However, combination therapy raises complex questions...
3.
4.
Chandler J, Rentz D, Zagar A, Kim Y, Schwartz R, Fillit H
Alzheimers Dement (Amst)
. 2023 Apr;
15(2):e12430.
PMID: 37091310
Introduction: GERAS-US prospectively characterized clinical and economic outcomes of early symptomatic Alzheimer's disease (AD). Societal cost changes were examined in amyloid-positive patients with mild cognitive impairment due to AD (MCI)...
5.
Ferrell P, Fillit H, Neumann P, Wall J, Murray J
Alzheimers Dement
. 2022 Nov;
19(4):1558-1567.
PMID: 36427013
Introduction: Assessing medical technologies for Alzheimer's disease (AD) creates challenges for current methods of value assessment. New value assessment approaches for AD are also needed. Methods: We adapted concepts from...
6.
Langbaum J, Zissimopoulos J, Au R, Bose N, Edgar C, Ehrenberg E, et al.
Alzheimers Dement
. 2022 Aug;
19(2):696-707.
PMID: 35946590
Clinical trials for Alzheimer's disease (AD) are slower to enroll study participants, take longer to complete, and are more expensive than trials in most other therapeutic areas. The recruitment and...
7.
Dawson W, Smith E, Booi L, Mosse M, Lavretsky H, Reynolds 3rd C, et al.
Innov Aging
. 2022 May;
6(3):igac016.
PMID: 35602311
Within many societies and cultures around the world, older adults are too often undervalued and underappreciated. This exacerbates many key challenges that older adults may face. It also undermines the...
8.
Meyers E, Amouyel P, Bovenkamp D, Carrillo M, De Buchy G, Dumont M, et al.
Alzheimers Dement
. 2021 Oct;
18(5):1067-1070.
PMID: 34596318
The COVID-19 pandemic has disproportionately affected more vulnerable populations, including those living with dementia. Over 50 million individuals worldwide are living with Alzheimer's disease (AD) or other dementia, and it...
9.
Herring W, Gould I, Fillit H, Lindgren P, Forrestal F, Thompson R, et al.
Neurol Ther
. 2021 Aug;
10(2):919-940.
PMID: 34426940
Introduction: Alzheimer's disease (AD) is a chronic and progressive neurodegenerative disease that places a substantial burden on patients and caregivers. Aducanumab is the first AD therapy approved by the US...
10.
Fillit H, Aigbogun M, Gagnon-Sanschagrin P, Cloutier M, Davidson M, Serra E, et al.
Int J Geriatr Psychiatry
. 2021 Jul;
36(12):1959-1969.
PMID: 34286877
Objectives: To describe characteristics and compare clinical outcomes including falls, fractures, infections, and neuropsychiatric symptoms (NPS) among long-term care residents with dementia with and without agitation. Methods: A cross-sectional secondary...